{
    "2020-08-21": [
        [
            {
                "time": "",
                "original_text": "暴漲161.47%！疫情或催生疫苗板块成最大赢家",
                "features": {
                    "keywords": [
                        "暴漲",
                        "疫情",
                        "疫苗板块"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物板块回撤-10%，哪些医药基金更抗跌？",
                "features": {
                    "keywords": [
                        "医药生物板块",
                        "回撤",
                        "医药基金"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【国元医药|点评】老百姓2020年中报点评：内生+外延扩张门店，加盟店模式加速发展",
                "features": {
                    "keywords": [
                        "国元医药",
                        "老百姓",
                        "中报",
                        "内生+外延扩张",
                        "加盟店模式"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "零售药店"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【国元医药|点评】万东医疗2020年中报点评：抗疫DR表现亮眼，毛利润率提升明显",
                "features": {
                    "keywords": [
                        "国元医药",
                        "万东医疗",
                        "中报",
                        "抗疫DR",
                        "毛利润率提升"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}